Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma

  • participants needed
  • sponsor
    Catalysis SL
Updated on 4 July 2022
platelet count
total bilirubin
white blood cell count
absolute neutrophil count
neutrophil count
folfox regimen
nutritional supplement
leukocyte count
colorectal adenocarcinoma
iv chemotherapy
metastatic colorectal adenocarcinoma


The research product, registered as a nutritional supplement (Ocoxin, oral solution), manufactured by Laboratorios Catalysis S. L., comes in the form of single-dose vials of 30 ml. It will be used at a rate of 60 ml daily (1 vial every 12 hours). Our main objective is To evaluate the effect of Ocoxin-Viusid on the quality of life of patients with metastatic colorectal adenocarcinoma. Our hypothesis is that the administration of the nutritional supplement Ocoxin-Viusid it is expected to improve the quality of life and enhance tolerance to chemotherapy in at least 70% of patients.


  • To evaluate the effect of Ocoxin-Viusid on the quality of life of patients.
    • To evaluate the influence of Ocoxin-Viusid on tolerance to onco-specific therapy.
    • Identify the changes that occur in the nutritional status of patients receiving the supplement.
    • To evaluate the toxicity of Ocoxin-Viusid in combination with chemotherapy in patients with metastatic colorectal adenocarcinoma.

Condition Colorectal Neoplasm, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasm, Rectal Diseases, Colonic Diseases, Intestinal Disease, Gastrointestinal Disease, Digestive System Disease
Treatment Ocoxin-Viusid
Clinical Study IdentifierNCT03559543
SponsorCatalysis SL
Last Modified on4 July 2022

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note